Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019628 | 0.83 | HPGD (0.62) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL2377572 | 0.72 | POLB (0.67) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL24019600 | 0.72 | ALDH1A1 (0.61) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL14635219 | 0.71 | ALDH1A1 (0.55) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL15878933 | 0.71 | ALDH1A1 (0.55) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL14635604 | 0.69 | ALDH1A1 (0.61) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3295146 | 0.68 | PTGS2 (0.49) | ALDH1A1HPGDMEN1KMT2ATSHR | |
| SCHEMBL24019794 | 0.68 | MAPT (0.61) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL10728985 | 0.68 | ALDH1A1 (0.64) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL2373727 | 0.66 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | ALDH1A1 1206/4885HPGD 2761/4885MAPT 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.